All News
Another biosimilar Adalimumab. SB5 switch in RA, PsA & SpA N=354 No diff in effectiveness Some minor flares. Some changed dose unsure why. #ACR2020 @RheumNow @CRASCRRheum abstr#805 https://t.co/2Zb4H2jBXQ
Janet Pope Janetbirdope ( View Tweet)
MEASURE2 and COAST-W data stratified by TNFi inadequate responders may suggest different axSpA subset (domain?) response to TNFi vs IL17i. Dr. J. Ermann #ACR20 @RheumNow #ACRbest https://t.co/0ZcEIvkuMj
Dr. Rachel Tate uptoTate ( View Tweet)
Which Axial SpA outcome score do you use in clinic as a target to achieve? @RheumNow #ACR20
Dr. Antoni Chan synovialjoints ( View Tweet)
In SpA-paz cohort 80% of axSpA pts achieved R or LDA at one visit, but only 40% maintained this level of disease control. #ABS0893 #ACR20 @RheumNow https://t.co/3MKBKOoNSw https://t.co/pTMJhtfKbU
Dr. Rachel Tate uptoTate ( View Tweet)
CZP tx in axSpA pts showed significant reduction of 82% in the AAU flare rate and MSK symptoms over 96 week C-VIEW trial. #ABS0881 #ACR20 @RheumNow https://t.co/bNFHXbKEuF https://t.co/3Z232vKGPC
Dr. Rachel Tate uptoTate ( View Tweet)
SKIPPAIN trial: SEC showed rapid and significant improvement of spinal pain (primary endpt) and ⬇ disease activity in axSpA @RheumNow #ACR20 abs0899 #ACRbest https://t.co/fKSEjwd6i9
sheila RHEUMarampa ( View Tweet)
Do you consistently address T2T in your axSpA patients in your clinical practice? List your measures below! #ACR20 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
T2T in clinical practice: Most axSpA pts had ≥1 annual ASDAS recorded, but target ID/LDA achieved in only 1/3 of pts at the first measurement. How do you address T2T in your practice? #ABS0879 #ACR20 @RheumNow https://t.co/Jy0mmqpHAb https://t.co/06fI10V3OZ
Dr. Rachel Tate uptoTate ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by Novartis. All content chosen by @RheumNow and its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Baseline characteristics differed between M/F pts w/ AS & nr-axSpA. Women were older at dz onset w/longer symptom duration & more joint dz and were less likely to be + HLA-B27 than men. Do you see this in your practice? #ABS0876 #ACR20 @RheumNow https://t.co/2goek1NiUW https://t.co/Uk8pmNP4Hr
Dr. Rachel Tate uptoTate ( View Tweet)
Pooled analysis from MEASURE 1-5 showed SEC was effective for AS regardless of HLA-B27 status. HLA-B27+ pts had more therapeutic benefit vs. HLA-B27- pts.
@RheumNow #ACR20 abs#0885 #ACRbest https://t.co/eD3ZGWxDkX
sheila RHEUMarampa ( View Tweet)
New treatments in Axial Spa at #ACR20. A significantly higher proportion of pts receiving Upadactinib vs placebo achieved reductions in all PGA of pain assessments and sustained to week 64 @RheumNow Abstr#369
Dr. Antoni Chan synovialjoints ( View Tweet)
Secukinumab has been used to treat spinal involvement in axial SpA. Secukinumab led to significant improvements in symptoms of peripheral arthritis in pts with AS. Significant improvements were seen in both tender and swollen joints @RheumNow #ACR20 Abstr#366
Dr. Antoni Chan synovialjoints ( View Tweet)
Check out my video on @rheumnow! #ACR20 Non-radiographic axSpa ACR Abstracts: Dr. Rachel Tate https://t.co/TVDdyZvOEA via @YouTube
Dr. Rachel Tate uptoTate ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Better outcomes (ASAS20 and ASAS40 @wk 52) seen in younger pts (possibly lower disease duration) when Secukinumab was given to ankylosing spondylitis pts. Early Dx in #AS! #ACR20 Abstr#0350 https://t.co/EKks0b1upc https://t.co/bxIH9lloI1
Dr. John Cush RheumNow ( View Tweet)
Emerging trend #MachineLearning - SpA expert Dr Dennis Poddubnyy talks at #ACR20 press conference - Development and Validation of an #artificial_intelligence Approach for the Detection of Radiographic Sacroiliitis using MRI @RheumNow
Bella Mehta bella_mehta ( View Tweet)
Who will be more likely to have chronic reactive arthritis @RheumNow #ACR20 @CRASCRRheum
Janet Pope Janetbirdope ( View Tweet)
ACHILLES study: Only 56% of pts w/ clinical enthesitis had MRI+ heel enthesitis. MRI screening: HLAB27+ pts likely to be in MRI+ grp. @RheumNow #ACR20 Abstr#0447 #ACRbest https://t.co/m2cjDzYfyg
sheila RHEUMarampa ( View Tweet)
Dr.Gonzalez-Mazon describes surrogate markers assoc'd w #atherosclerosis in #axSpA: BASFI, BASMI, IBD, ESR, CRP, prednisone and DMARDs use. @RheumNow #ACR20 abst#0448 https://t.co/g27qA4qpPL
sheila RHEUMarampa ( View Tweet)
